期刊
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS
卷 26, 期 4, 页码 310-320出版社
SAGE PUBLICATIONS INC
DOI: 10.1177/1074248420987445
关键词
CABG; secondary prevention; antiplatelets; statins
Secondary prevention after coronary artery bypass graft surgery involves different medication needs and responses for patients compared to the general cardiovascular population. Current drug regimens include aspirin, statins, and clopidogrel, but the effectiveness of some of these medications is debatable. There is a need for robust population-specific evidence in certain areas, which future research should address.
Secondary prevention after coronary artery bypass graft (CABG) surgery is imperative in slowing the progression of atherosclerosis in both native and grafted vessels. Aspirin and statins remain the key medications for all patients without significant contraindications. The evidence for dual antiplatelet therapy with clopidogrel is less convincing, but there is hope for newer antiplatelet agents, such as ticagrelor. Meanwhile, beta-blockers and angiotensin converting enzyme inhibitors might only offer benefits to specific sub-groups. Post-CABG patients appear to have different medication needs to the general cardiovascular patient and respond differently. In this review, we cover the drug regimens proposed by recent guidelines and the evidence behind their use. Assessing the evidence behind these recommendations, we find that there is an unmet need in some areas for robust population-specific evidence. We hope that future research will address this gap.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据